The collaboration aims to further validate the ArteraAI Prostate Test in the Hispanic population
ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announced a research agreement with CorePlus, a high complexity CLIA-certified clinical and anatomic pathology laboratory headquartered in Carolina, Puerto Rico. The collaboration aims to further validate The ArteraAI Prostate Test in the Hispanic population
“We are committed to ensuring that our models are trained on datasets that properly represent diverse patient populations,” said Andre Esteva co-founder and CEO of ArteraAI. “Working with CorePlus allows us to enhance our diversity efforts, providing a unique opportunity to conduct comprehensive analytical validation of our models across diverse ethnic groups.”
Recommended AI News: Riding on the Generative AI Hype, CDP Needs a New Definition in 2024
Recommended AI News: Multiagency Investment In AI-Driven Data Harmonization
Prostate cancer is the most commonly diagnosed cancer among Hispanic men in the U.S., comprising more than 1 in 5 of all new cancer diagnoses. Research also shows that 7.2% of Hispanic men who are diagnosed with prostate cancer die from their disease, making it the 4th leading cause of cancer death among this population. In fact, prostate cancer-specific mortality has been shown to be highest in Puerto Rican men, higher than even non-Hispanic blacks.
“We are thrilled to collaborate with ArteraAI to further the advancement and reduction of inequities in prostate cancer diagnosis and treatment,” said Mariano de Socarraz, CEO of CorePlus. “This research agreement provides a strong step forward in increasing understanding of differences and reducing disparities in access to precision diagnostics creating more equitable and personalized care for prostate cancer patients.”
Recommended AI News: Copado Expands Beta Access to CopadoGPT for All Customers, Revolutionizing SaaS DevOps with AI
ArteraAI remains committed to incorporating diverse datasets in the training of its AI models, with CorePlus marking the latest endeavor. This collaborative effort extends the work of ArteraAI’s MMAI models, which were deliberately developed using cohorts comprising approximately 20% African Americans— a percentage that mirrors the 16% prevalence of prostate cancer in this specific patient population. The research alliance with CorePlus will provide ArteraAI access to an extensive database of Hispanic patients. CorePlus has applied a prostate-specific artificial intelligence algorithm on more than 10,000 men.
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.